DAVID DRANEY: Open Payments
NPI 1891141644 · SEARCY, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,845 in 99 payments from 13 companies in 2025. Trend: 2023 $1,605 · 2024 $1,987 · 2025 $1,845
Food & beverage: $1,765Education: $80
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 35 | $596 |
| Otsuka America Pharmaceutical, Inc. | 12 | $215 |
| Neurocrine BioSciences, Inc. | 9 | $196 |
| Teva Pharmaceuticals USA, Inc. | 9 | $192 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $147 |
| Janssen Pharmaceuticals, Inc | 7 | $124 |
| Lundbeck LLC | 7 | $113 |
| Supernus Pharmaceuticals, Inc. | 3 | $81 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| E.R. Squibb & Sons, L.L.C. | 2 | $43 |
Products named: VRAYLAR, REXULTI, INGREZZA, CAPLYTA, INVEGA SUSTENNA, ABILIFY ASIMTUFII, Qelbree, UZEDY.
Industry payments across AR — which companies pay providers there.
